相关实验视频
Updated: Sep 11, 2025
08:39
Murine Colitis Modeling using Dextran Sulfate Sodium DSS
Published on: January 19, 2010
50.2K
低分子量阿斯特拉加勒斯膜的多糖减轻了牛硫酸诱导的大肠炎在小鼠
Meng Ye1, Menghan Fan1, Yi Zhao1
1Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, PR China.
Carbohydrate polymers
|August 16, 2025
概括
与分支结构 (APS-A1) 相比,具有线性结构 (APS-G2) 的阿斯特拉加卢斯膜状多糖 (APS) 对炎症性肠病 (IBD) 显示出优越的抗炎作用. 酶修饰增强了APS治疗IBD的治疗潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 目前的炎症性肠病 (IBD) 治疗方法在有效性和副作用方面存在局限性.
- 阿斯特拉加勒斯膜多糖 (Astragalus membranaceus polysaccharides,简称APS) 具有抗炎性质,但其结构与活性之间的关系尚不清楚.
研究的目的:
- 为了比较线性APS-G2和分支APS-A1在IBD上的治疗效果.
- 在IBD管理中阐明APS衍生品的结构功能关系.
- 为了研究APS-G2疗效的潜在分子机制.
主要方法:
- 酶性衍生APS成线性 (APS-G2) 和分支 (APS-A1) 寡糖.
- 在DSS诱导的IBD模型中评估治疗效果.
- 对促炎和抗炎细胞因子水平的分析.
- 评估肠道屏障的完整性,包括亡和紧结蛋白表达.
- 对SIRT1/PGC-1α/NF-κB和FXR信号通路的研究.
主要成果:
- 与分支的APS-A1.1相比,APS-G2的线性α-1,4-葡萄糖结构对于优越的生物活性至关重要.
- APS-G2显著降低了促炎细胞因子,增加了抗炎介质.
- APS-G2通过抑制细胞灭绝和促进紧结蛋白表达,增强了肠道屏障的完整性.
- APS-G2调节了SIRT1/PGC-1α/NF-κB和FXR介导的信号通路.
结论:
- APS-G2的一致的线性α-1,4-葡萄糖骨干对于其在IBD中强大的抗炎作用至关重要.
- APS的酶工程可以增强其在炎症性肠病中的治疗潜力.
- 准SIRT1/PGC-1α/NF-κB和FXR通路是APS-G2在IBD疗效的关键机制.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
237
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
237
01:17Drugs for Treatment of Diarrhea-Predominant IBS
294
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
294
01:21Drugs for Treatment of Constipation-Predominant IBS
333
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
333
01:20Drugs Affecting GI Tract Motility: Other Laxatives
460
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
460